 |
Product Search
|
 |
|
Article Search
|
|
|
Resources
| |
|
Home > PPX - A New Stock Market Simulator From The Minds Behind Hollywood Stock Exchange
We Have Found 7 Products for your search of PPX - A New Stock Market Simulator From The Minds Behind Hollywood Stock Exchange.
Displaying Items 1 - 7 and News Search:
- Shahnaz Husain Group Opens Shahnaz Herbal Salon At Kolkata
Sat, 07 Aug 2010 00:58:44 -0700 Addressing on the occasion, the director of INKAT Beauty Salon, Mr Kajal Bhattacharyya said, "Shahnaz Herbal has been a unique personalized salon services that offers precise and individual services.
- Press Release
Wed, 04 Aug 2010 06:48:02 -0700 Merck today reported that two pivotal Phase III registration studies for boceprevir, its investigational oral hepatitis C protease inhibitor, have been completed and met the primary endpoints: in both studies in patients with chronic hepatitis C virus (HCV) genotype 1 infection, the addition of boceprevir to treatment with PEGINTRON ® (peginterferon alfa-2b) and REBETOL ® (ribavirin, USP) (Peg ...
- In Pivotal Phase III Studies, Merck's Investigational Medicine Boceprevir Helped Majority of Patients with Chronic ...
Wed, 04 Aug 2010 05:09:00 -0700 WHITEHOUSE STATION, N.J.----Merck today reported that two pivotal Phase III registration studies for boceprevir, its investigational oral hepatitis C protease inhibitor, have been completed and met the primary endpoints: in both studies in patients with chronic hepatitis C virus genotype 1 infection, the addition of boceprevir to treatment with PEGINTRON® and REBETOL® significantly increased the ...
- Merck reports strong bottom-line performance in second quarter
Mon, 02 Aug 2010 03:06:35 -0700 Merck & Co., Inc. today announced financial results for the second quarter of 2010. The company reported non-GAAP (generally accepted accounting principles) earnings per share (EPS) for the second quarter of $0.86, which excludes purchase accounting adjustments, merger-related expenses, restructuring costs and the gain on AstraZeneca's asset option exercise. Second-quarter GAAP EPS was $0.24.
- Merck Grants License to LabCorp for Development of Test To Potentially Identify Patients Likely to Respond to ...
Tue, 27 Jul 2010 13:08:00 -0700 WHITEHOUSE STATION, N.J.----Merck today announced a non-exclusive license agreement with Laboratory Corporation of America® Holdings for the commercialization of a genetic test that may help predict the response of patients with Hepatitis C virus infection to peginterferon alpha-based therapy.
- Integrative Medicine Center Holds Webinar on Thyroid Disease
Mon, 26 Jul 2010 03:00:00 -0700 Cutting-Edge Information for Those with Hypothyroid and Hyperthyroid Conditions
|
